Protocol Ledger

NCT06974786 · Phase II · RECRUITING

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Interventional Phase II clinical trial protocol NCT06974786 sponsored by SCRI Development Innovations in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-08 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06974786
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06974786
Protocol FieldVerified Registry Value
NCT IdentifierNCT06974786
Consolidated Lead SponsorSCRI Development Innovations
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2025-08-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06974786
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Colorado Blood Cancer InstituteDenver, COOpen Hospital Dossier ->
University of IowaIowa City, IAOpen Hospital Dossier ->
University of North CarolinaChapel Hill, NCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI